Our Medical Affairs team provides flexible and agile services to pharmaceutical companies.
Our scientific advisors deliver flexible and agile support to pharmaceutical companies.
Our Medical Affairs team provides agile support to our pharmaceutical clients, both in healthcare settings and office environments. We offer comprehensive assistance from ideation and planning through to the preparation of medical documentation. Whether you are preparing for a new product launch or managing the lifecycle of established products, our experienced experts are ready to help. Our services encompass scientific communication with healthcare professionals, evaluations of healthcare environments, and flexible staffing solutions, including task-specific outsourcing such as material reviews for pharmaceutical companies.
Since 2009, Medaffcon has been providing its Medical Affairs services, continuously enhancing its offerings for over 15 years. Project durations vary, ranging from a few weeks to several months. For instance, a literature search may take two weeks, whereas a comprehensive scientific market assessment and market potential analysis prior to a new product launch could span several months. Within pharmaceutical companies, our primary contacts typically include key members of the medical department such as the Medical Director or Medical Affairs Lead, as well as commercial managers responsible for the product, like Brand Managers or Business Unit Managers.
Medaffcon is a dynamic and experienced partner, delivering agile, solution-oriented support for the Medical Affairs projects and needs of pharmaceutical companies.//
Medaffcon is an experienced and agile partner, offering expert, solution-oriented services for the medical project needs of pharmaceutical companies.
Our extensive experience, reliability, and dedicated experts have consistently driven high customer satisfaction, as evidenced by our Net Promoter Score (NPS) of over 70.
Patient-centricity was one of the key themes at ISPOR Europe in Barcelona this November. Participants also discussed topics such as the use of Real-World Evidence (RWE) in Health Technology Assessment (HTA) and the significance of artificial intelligence. In this article, Medaffcon's ISPOR attendees share the most important themes from this year's event.
Sweden and Finland are leaders in developing and applying health technology and provide ideal environments for conducting Health Technology Assessments (HTA) for medical devices.
Medaffcon's operations in Sweden are well-established and growing, offering pharmaceutical companies RWE studies and Market Access services delivered by Data Scientists, Market Access experts, and RWE specialists working together. A key therapeutic area is oncology.
Sales Lead
eMBA
+358 50 305 5963
tomi.vahevaara@medaffcon.fi
Tomi Vahevaara started working at Medaffcon in January 2017 as a Sales Director. He has been working in the pharmaceutical industry for over 35 years. Therefore, he has gained wide-ranging experience in international expert and managerial positions within the innovative pharmaceutical industry. Before joining Medaffcon, Tomi worked for ten years as the Managing Director of Eli Lilly for Finland, the Baltic States, and Poland.
Tomi has solid and wide-ranging expertise in different positions in the pharmaceutical field and is well connected in the entire health industry network. He serves as the Chairman of the Board of the Finnish Mutual Insurance Company for Pharmaceutical Injury Indemnities and as a Board Member in the Finnish Co-operative for Pharmaceutical Injury Indemnities. Tomi is particularly interested in the significant economic and investment opportunities for Finland and those companies working in the Finnish health industry.
Principal Consultant
MSc (Economics)
+358 40 139 4001
jarmo.hahl@medaffcon.fi
Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry, he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.
Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment.
“From an access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole”.